


2Q 2005 Financial Results

Analyst Meeting 10 August 2005



Forward looking statement

Any statement contained in this presentation that refers to Actavis' estimated or anticipated future results or future activities are forward-looking statements which reflect the Company's current analysis of existing trends, information and plans. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially depending on factors such as the availability of resources, the timing and effect of regulatory actions, the success of new products, the strength of competition, the success of research and development issues, unexpected contract breaches or terminations, exposure to product liability and other lawsuits, the effect of currency fluctuations and other factors. Actavis does not undertake the obligation to update or alter these forward-looking statements beyond its duties as an issuer of listed securities on the Iceland Stock Exchange.

Agenda

1. Financial results
2. Sales performance
 - Own label
 - Third party
4. Chief executive appointment
5. Outlook
6. Q&A



Financial highlights



Financial highlights 2Q

2Q 2005 Highlights

- Total revenue up 14.4%
- Own Label sales up 27.9% with
- EBITDA and profit below expectations
- Delivery issues in Iceland slowing Third Party sales
- Price reduction in Turkey in July
- First to market with Benazapril Hydrochlorothiazide and Fosinopril
- Lamotrigine launched in nine European countries
- Lotus Laboratories acquired in April Acquisition of Amide in May
- Successful rights issue in Iceland

Key Financials 2Q

	2Q 2005	2Q 2004	% Change
Operating revenues.....	121,989	106,622	14.4%
Total operating expenses.....	(105,409)	(86,886)	21.3%
EBITDA.....	23,445	24,747	-5.3%
EBIT.....	16,580	19,736	-16.0%
Profit before tax.....	16,093	12,228	31.6%
Taxes.....	(4,802)	(2,175)	120.8%
Net profit.....	11,291	10,053	12.3%
Underlying Growth.....	11.4%	11.5%	-0.1%
Earnings per share (EPS).....	0.00354	0.00359	-1.4%

Financial highlights 1H

1H 2005 Highlights

- Total revenue down 5.1%
- Strong growth in all key Own Label markets
- Completion of Amide acquisition
- 600 million loan facility
- Group expected to be on target for the full year

Key Financials 1H

	1H 2005	1H 2004	% Change
Operating revenues.....	223,779	235,881	-5.1%
Total operating expenses.....	(188,328)	(185,934)	1.3%
EBITDA.....	48,010	59,802	-19.7%
EBIT.....	35,451	49,947	-29.0%
Profit before tax.....	27,765	39,867	-30.4%
Taxes.....	(5,381)	(7,990)	-32.7%
Net profit.....	22,384	31,877	-29.8%
Underlying Growth.....	-6.8%	15.8%	-22.6%
Earnings per share (EPS).....	0.00725	0.01110	-34.7%




Financial highlights 1H

Revenues by segments

1H 2004

1H 2005




Financial highlights 1H


Sales by geographic region

1H 2004


1H 2005



Revenues by quarter




EBITDA to revenue




Cost ratios development


EUR million



Balance sheet Assets



Balance sheet Equity & liabilities



Cash Flow EUR '000

	1H 2005	1H 2004
Working capital from operating activities	53,556	42,832
Net Cash provided by operating activities	37,807	16,691
Investing activities	-63,213	-25,253
Financing activities	84,367	-1,401
Net change in cash and cash equivalents	58,961	-9,963
Effects of foreign exchange adjustments	1,927	369
Cash and cash equivalents at beginning of period	17,325	29,968
Cash and cash equivalents at end of period	78,213	20,374

Sales performance



Divisional overview

Main divisions for sales of products and intellectual property

Sales & Marketing, International (Own-Label)

- Own-label products developed by Actavis or in-licensed from other companies, but in Actavis livery
- Key markets include Turkey, Bulgaria, Russia, Serbia and Scandinavia

Sales & Marketing, Third-Party Global

- Sales of products developed by Actavis to third parties
- Key markets include Germany, Austria, the Netherlands, Spain and Denmark

North America Division

- Affects Actavis results from beginning of July
- Sales of Own Label products




Own-Label sales by quarters

	1Q 2005	2Q 2005	2Q 2004	1H 2005	1H 2004
Sales	64.2	73.2	57.2	137.4	112.8
% of Group Revenues	63.0%	60.0%	53.7%	61.4%	47.8%
Underlying Growth	14.0%	26.6%	6.8%	20.4%	-1.5%

• Highlights for 2Q and H1


- Sales up 28% in 2Q, 22% for 1H
- Own-label represented 61.0% of the Group's revenue in 1H
- Strong growth in all key markets
- Continued pressure on prices in Turkey
- Number of new product launches in all key markets
- Focus on integration work of latest acquisitions of Own Label marketing companies
- Performance in line with expectations

Total EUR137.4 million




Top 10 products account for 35% of Own-Label sales

Own-Label sales by markets
1H 2005



Own-Label sales by therapeutic classes
1H 2005





Own-Label - key markets

Turkey - 39% of division sales

- Strong growth from 2004, sales up 54.0% in 2Q and up 37.1% in H1
- Government imposed price decreases - pressure on margins
- Solid growth expected in second half

Bulgaria - 18% of division sales

- Sales up 8.4% in 2Q and up 5.2% in H1
- New reimbursement levels with authorities expected to generate more revenue in coming months
- Number of new product launches in H1
- Good outlook with number of new products launched in second half





Own-Label - key markets

Russia, Ukraine & CIS - 20% of d.sales

- Excellent growth from 2004 of 26.6% in 2Q and up 32.3% in H1
- Three new market launches with several new launches in H2
- Performance exceeded expectations

North Europe - 11% of division sales

- Negative growth of 2.4% from 2004 in Q2 and -0.5% in H1
- Performance under expectations
- Competition remains but number of launches in H2 supporting growth



Third-Party Sales



Sales development EUR60.1 million

Third-Party sales by quarters - highlights


	1Q 2005	2Q 2005	2Q 2004	1H 2005	1H 2004
Sales	26.8	33.3	38.6	60.1	112.8
% of Group Revenues	26.3%	27.3%	36.2%	26.8%	47.8%
Underlying Growth	-54.6%	-13.8%	22.2%	-38.5%	41.4%

Highlights for 2Q and H1 2005

- Performance under expectations for 2Q
- Delivery constraints in 2Q in Icelandic manufacturing site, due to complicated launches
- Three product launches in Q2
 - First to market with Benazapril Hydrochlorothiazide in Germany
 - First to market with Fosinopril in UK and the Netherlands
 - Lamotrigine (two forms) launched in nine different EU countries
- Sale of intellectual property above expectations

Third-Party - H1 Total EUR60.1 million


Sales by segments



Intellectual Property

- 6.2 million, up 16% over 2004
- Revenue from 28 products


Sales by therapeutic class



Finished products


- 53.8 million, down 42% over 2004
- Revenue from 32 products

Third-Party sales by markets - H1 Finished products total EUR53.8 million




*Market split excludes intellectual property

Third-Party - H1 Top 10 products



Top 10 products account for 76% of finished products sales

Chief executive appointment





Mark Keatley Chief Executive of Finance



- Joins Actavis from Farmar SA, the leading European contract manufacturer of pharmaceuticals
- 10 years experience at Board level as CFO at international companies
- Prior experience as an investment banker - International Finance Corporation in Washington DC

- Been through the process of two stock exchange listings, in London and New York
- Holds an MBA degree from Stanford Business School, USA,
- MA in History
- Qualified accountant in the UK where he is a member of the UK Chartered Institute of Management Accountants



Outlook

- The Group is expected to show strong progress in second half
- Amide incorporated into Group's accounts from beg. of July - significantly supporting growth and margins
- Own Label division expected to continue to deliver strong growth
- Third Party division is expected to show improvement in H2 but still to show a slightly reduced sales over 2004
- Third quarter expected to show good improvement in margins and growth and fourth quarter with strongest growth and margins

The Group expected to be on target with 26% for full year and underlying growth in single digits



Investor & Media Relations:

Robert Wessman, President & CEO

Tel: +354 535 2300

Halldór Kristmannsson, Corporate comm.

Tel : +354 535 2300/
+354 840 3425

Financial Dynamics - London

David Yates, Julia Phillips

Tel: +44 (0) 207 831 3113

Financial Dynamics - NY

Charles Armitstead

Tel: (+1) 212 850 5600